ASCO 2015 Highlights

CMS’s Coverage Decision on Provenge: Implications for Payers
By Dalia Buffery, MA, ABD
Health Policy, Policies & Guidelines
April 2011, Vol 2, No 2
On March 30, 2011, the Centers for Medicare & Medicaid Services (CMS) announced its highly anticipated proposed national coverage decision concerning the prostate cancer immunotherapy sipuleucel-T (Provenge; Dendreon).
Read Article
Accelerating Growth in REMS Programs a Challenge for Oncologists
By Daniel Denvir
ACCC Conference
April 2011, Vol 2, No 2
Addressing the 2011 Association of Community Cancer Centers annual meeting attendees, Timothy Tyler, PharmD, FCSHP, Director of Pharmacy Services at the Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, CA, outlined the considerable demands and complications that have been added to oncology care with the introduction of the Risk Evaluation and Mitigation Strategies (REMS) program for high-risk drugs.
Read Article

Page 317 of 329

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.